OVARIAN CANCER

This early-phase study tested the safety of a new drug, INCB062079, in 25 people with advanced liver cancer or other solid tumors. The goal was to find a safe dose and see how well patients tolerated the treatment. The study was terminated early, so results are limited.

This study tested a radioactive drug called [225Ac]-FPI-1434 in people with advanced solid tumours that had not responded to standard treatments. The goal was to find a safe dose and see if it could shrink tumours. The trial was stopped early, so results are limited. Participants…

This study looked at whether adding a third drug (fluzoparib) to a two-drug combination (apatinib and letrozole) helps control recurrent ovarian cancer longer. It included adults with a specific type of ovarian cancer that had responded to prior treatment. The study was stopped e…

This study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique mutations in their cancer. It was designed for people with advanced solid tumors like lung, pancreatic, or ovarian cancer who had not responded to s…

This study tested a new drug called OC-001, either by itself or combined with avelumab (an immunotherapy), in people with advanced cancers that had spread. The goal was to check safety and how the drug moves through the body. The trial was stopped early, and only 73 people were e…

This study tested a new drug (SOT101) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combo could shrink tumors. The trial was stopped early, and it is not a cure—patients still need ongoing tre…

This study tested a new drug called NUV-868, alone or with other cancer drugs (olaparib or enzalutamide), in 82 adults with advanced solid tumors like ovarian, pancreatic, prostate, or breast cancer. The main goals were to check safety and find the right dose. The trial was stopp…

This early-stage study tested an experimental oral drug called NKT3447 in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in people with advanced solid tumors like breast, kidney, ovarian, head and neck, colorectal, lung cancer, or melanoma. The goal was to check safety and see if tumors shrank. The st…

This early-phase study tested a new drug called PHN-010, which delivers a powerful toxin directly to cancer cells. It involved 26 adults with advanced lung, colon, endometrial, ovarian, or cervical cancers that had already been treated. The main goals were to check safety and fin…

This study tested a new drug called BLU-222 in people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if it could shrink tumors. The trial was stopped early, so results are limited.

This early-phase study tested a new drug called SO-C101, alone or with pembrolizumab, in 115 people with advanced solid tumors (like lung, kidney, or skin cancer) that stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study …

This study tested a new drug called luveltamab tazevibulin against standard chemotherapy in about 600 women whose ovarian cancer had stopped responding to platinum-based treatment. The drug targets a protein (FOLR1) found on many ovarian cancer cells. The trial was terminated ear…

This early-phase study tested a new treatment for women with ovarian, fallopian tube, or peritoneal cancer that returned or didn't respond to standard therapy. The approach involved taking a type of white blood cell (monocytes) from each participant, activating them with immune-b…

This study tested whether combining two drugs, alpelisib and olaparib, works better than standard chemotherapy for people with a certain type of advanced ovarian cancer that no longer responds to platinum-based chemo. The trial included 358 adults whose cancer had returned or res…

This early-phase study tested a new drug (STRO-002) combined with bevacizumab in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal was to check safety and find the right dose. The study was stopped early, so results are limited.

This study tested a combination of two drugs, copanlisib and fulvestrant, in people with advanced endometrial or ovarian cancers that are hormone receptor-positive and have certain gene changes (PI3K/PTEN). The goal was to see if the combination was safe and effective. Only 7 peo…

This study tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The goal was to check safety and see if the drug could shrink tumors. The trial was stopped early, so results are limited.

This study tested three different doses of an experimental drug called AUR 109 in 29 adults with advanced colorectal, ovarian, or kidney cancer who had already tried at least two other treatments. The goal was to see if the drug could shrink tumors and to check its safety. Howeve…

This study collected fluid from the abdomen or lungs, plus blood, from 22 adults with solid tumors. The goal was to learn more about how cancer works, not to test a new treatment. Researchers hope this knowledge will lead to better therapies in the future.

This study aimed to measure how platinum resistant ovarian cancer affects the quality of life of patients and their caregivers in Canada. Researchers used questionnaires to assess symptoms, work productivity, and overall well-being. The goal was to highlight the challenges and un…

This study looked at 289 people with early-onset breast, ovarian, colorectal, or pediatric cancers, plus those with multiple tumors. Researchers used a special test to check 200 genes for inherited mutations that standard tests might miss. The goal was to better understand why th…